Resistance to targeted therapies in breast cancer
We present an in-depth description of resistance to targeted therapies in breast cancer. Targeted therapies discussed here include those used to treat ER+ or Her2+ breast cancers (i.e., Tamoxifen or trastuzumab) or those targeting signaling pathways aberrantly activated in triple negative breast can...
Saved in:
| Other Authors | |
|---|---|
| Format | Electronic eBook |
| Language | English |
| Published |
Cham, Switzerland :
Springer,
[2017]
|
| Series | Resistance to targeted anti-cancer therapeutics ;
v. 16. |
| Subjects | |
| Online Access | Full text |
| ISBN | 9783319701424 9783319701417 |
| ISSN | 2196-551X ; |
| Physical Description | 1 online resource |
Cover
| Summary: | We present an in-depth description of resistance to targeted therapies in breast cancer. Targeted therapies discussed here include those used to treat ER+ or Her2+ breast cancers (i.e., Tamoxifen or trastuzumab) or those targeting signaling pathways aberrantly activated in triple negative breast cancer (i.e., EGFR and Wnt signaling). We have also provided an overview of standard of care as an introduction into the importance of targeted therapy. It is our hope that this volume gives an insight into the landscape of breast cancer treatment, the challenges of targeted therapy, and a glimpse into the future of breast cancer therapy. #xE000. |
|---|---|
| Bibliography: | Includes bibliographical references and index. |
| ISBN: | 9783319701424 9783319701417 |
| ISSN: | 2196-551X ; |
| Access: | Plný text je dostupný pouze z IP adres počítačů Univerzity Tomáše Bati ve Zlíně nebo vzdáleným přístupem pro zaměstnance a studenty |
| Physical Description: | 1 online resource |